治疗尿路上皮癌新药:成纤维细胞生长因子受体酪氨酸激酶抑制剂erdafitinib

A new drug in treatment of urothelial carcinoma: fibroblast growth factor receptor tyrosine kinase inhibitor erdafitinib

erdafitinib (Erd)为一种口服给药的泛成纤维细胞生长因子受体(FGFR)酪氨酸激酶抑制剂,由杨森制药公司生产,于2019年4月12日获美国食品和药物管理局加速批准用于治疗局部晚期或转移性尿路上皮癌成人患者。临床试验表明,FGFR突变的晚期或转移性尿路上皮癌患者接受Erd治疗可取得较好的疗效。Erd治疗相关的3级及以上不良事件包括口腔炎、手足综合征、角膜炎及高磷酸盐血症等,通过调整剂量,患者一般可耐受。

Erdafitinib(Erd) is an orally administered pan-fibroblast growth factor receptor(FGFR) tyrosine kinase inhibitor. It has been approved by U.S. Food and Drug Administration in the treatment of adult patients with locally advanced or metastatic urothelial carcinoma(UC) on April 12, 2019 and manufactured by Janssen Pharmaceutical Ltd. Clinical trials have shown that Erd has a better therapeutic effect in treating patients with advanced or metastatic UC with FGFR mutation. Erd treatment-related adverse events of grade 3 or higher include stomatitis, hand-foot syndrome, keratitis and hyperphosphatemia,and patients are generally well tolerated by adjusting the dose.